French Anderson sentenced to 14 years

French Anderson was sentenced today (Feb 2) to 14 years in prison, after he was linkurl:found guilty;http://www.the-scientist.com/news/display/23996/ last summer of four counts of molestation. His victim, now 19 years old, is the daughter of his colleague, and the abuse started when she was 10 years old. Soon after the conviction, the University of Southern California (USC) released a statement that it had suspended Anderson and was initiating dismissal proceedings to remove his tenure and fac

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
French Anderson was sentenced today (Feb 2) to 14 years in prison, after he was linkurl:found guilty;http://www.the-scientist.com/news/display/23996/ last summer of four counts of molestation. His victim, now 19 years old, is the daughter of his colleague, and the abuse started when she was 10 years old. Soon after the conviction, the University of Southern California (USC) released a statement that it had suspended Anderson and was initiating dismissal proceedings to remove his tenure and faculty position, calling his actions a "grave offense" to the USC community. Anderson linkurl:claimed;http://www.the-scientist.com/article/display/22328/ to have led the first team to carry out an approved human gene therapy clinical protocol, in September 1990. During the treatment, Anderson and his colleagues used a retrovirus to insert genes into the T lymphocytes of a 4-year-old girl suffering from severe combined immunodeficiency, or SCID, caused by a deficiency in the adenosine deaminase gene. Anderson had focused his recent research on gene therapy delivery systems. Before joining the University of Southern California, Anderson spent 27 years as a gene therapy researcher at the National Heart, Lung, and Blood Institute at the National Institutes of Health. To date, Anderson has published almost 400 research articles and been profiled by a number of publications, including the New York Times and Scientific American. See The Scientist daily news on Monday for more coverage.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies